Rapport Therapeutics, Inc. Common Stock
RAPPNASDAQHealthcare● Active
$38.11
+$1.43(+3.90%)
Market Cap$1.4B
P/E Ratio—
52W High$42.269
52W Low$10.505
Rapport Therapeutics, Inc. Common Stock（RAPP）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · RAPP · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | ($0.11B) | ($0.08B) | ($0.03B) | ($0.01B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.00B | $0.01B | $0.00B | $0.00B |
| Change in Working Capital | $0.00B | ($0.00B) | $0.00B | $0.00B |
| Net Cash from Operations | ($0.09B) | ($0.06B) | ($0.03B) | ($0.00B) |
| Investing Activities | ||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | $0.00B | ($0.38B) | ($0.08B) | $0.00B |
| Sales of Investments | $0.00B | $0.21B | $0.00B | $0.00B |
| Net Cash from Investing | ($0.19B) | ($0.17B) | ($0.08B) | ($0.01B) |
| Financing Activities | ||||
| Common Stock Repurchased | $0.00B | $0.00B | ($0.00B) | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.01B |
| Net Cash from Financing | $0.27B | $0.22B | $0.15B | $0.04B |
| Free Cash Flow | ||||
| Free Cash Flow | ($0.09B) | ($0.07B) | ($0.03B) | ($0.00B) |
| FCF Margin %(computed) | — | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Rapport Therapeutics, Inc. Common Stock
关于Rapport Therapeutics, Inc. Common Stock（RAPP）现金流量表
Rapport Therapeutics, Inc. Common Stock 2025财年经营活动现金流($0.09B)，自由现金流($0.09B)（FCF利润率—），资本支出($0.00B)。
常见问题
RAPP · 4 问Rapport Therapeutics, Inc. Common Stock 2025财年自由现金流($0.09B)，同比down31.0%。
RAPP free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10